GMPタンパク質受託製造の世界市場

GMPタンパク質受託製造の世界市場は2030年までに13億米ドルに達する見込み

2024年に8億70万米ドルと推定されるGMPタンパク質受託製造の世界市場は、2024～2030年の分析期間にCAGR 8.0％で成長し、2030年には13億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるサイトカインは、CAGR6.1%を記録し、分析期間終了時には3億1,310万米ドルに達すると予測されます。成長因子セグメントの成長率は、分析期間中CAGR 9.9％と推定されます。

米国市場は2億1,810万米ドルと推定、中国はCAGR12.2％で成長予測

米国のGMPタンパク質受託製造市場は、2024年に2億1,810万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR12.2％を引きずる形で、2030年までに2億6,790万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.2%と7.6%と予測されています。欧州では、ドイツがCAGR 5.3%で成長すると予測されています。

世界のGMPタンパク質受託製造市場- 主要動向と促進要因まとめ

今日のバイオ医薬品においてGMPグレードのタンパク質製造が重要なのはなぜか？

GMP（Good Manufacturing Practice）タンパク質受託製造は、厳しい規制基準を満たす治療用タンパク質、酵素、生物製剤の製造において基礎的な役割を果たしています。臨床試験や市販の治療薬に使用されることが多いこれらのタンパク質は、安全性、一貫性、有効性を確保するため、厳密に管理された条件下で製造されなければなりません。GMPに準拠した施設を社内に設置するのは複雑でコストがかかるため、多くの製薬会社やバイオテクノロジー企業は、有効なGMPインフラと規制上の経験を持つ専門の製造受託機関（CMO）にタンパク質製造のニーズをアウトソーシングしています。このモデルは資本支出を削減するだけでなく、競争が激しくイノベーション主導の業界において市場投入までの時間を短縮します。

特にモノクローナル抗体、サイトカイン、融合タンパク質、治療用酵素など、生物製剤が新薬パイプラインの主流を占める中、高品質でGMP準拠のタンパク質製造に対する需要は急増し続けています。これらのタンパク質はプロセス条件に対して非常に敏感であることが多く、高度な発現システム（細菌、酵母、哺乳類、または昆虫細胞）、正確な精製プロトコル、および強固な品質保証フレームワークを必要とします。GMPタンパク質製造サービスには、上流の細胞株開発、スケールアップ、精製、製剤化、充填仕上げ、リリーステストが含まれ、すべてが厳格な規制監督の下に行われます。このような特殊なプロセスにおいてCMOへの依存が高まっている背景には、規制当局への申請手続きや、様々な臨床規模・商業規模での生産可能な材料の提供において、CMOが実績を上げていることがあります。

バイオテクノロジーの動向と医薬品開発ニーズは、CMOのサービス内容をどのように変化させているか？

バイオテクノロジーパイプラインの進化により、受託製造企業は、多様なタンパク質の種類、複雑な分子構造、開発期間の短縮に対応するため、サービス能力の拡大を余儀なくされています。オーファンドラッグ、希少疾患向け生物製剤、個別化治療のパイプラインへの参入が増加する中、CMOは少量臨床材料から大規模商業生産まで対応できる柔軟なモジュール式GMP施設に投資しています。シングルユースバイオリアクター、ハイスループット精製システム、連続処理法などが採用され、スケーラビリティの向上、交差汚染リスクの低減、運用コストの削減が図られています。

CMOが遺伝子合成やプラスミド設計からGMPグレードのタンパク質発現や最終製剤化まで、エンド・ツー・エンドのサービスを提供します。このワンストップショップモデルは、創薬から臨床開発への迅速な移行を可能にし、特に社内の能力が限られている新興企業やバーチャルバイオテックにとって価値があります。さらに、細胞治療、遺伝子治療、ワクチン製造に使用される組換えタンパク質の需要が増加しているため、CMOは高収率、高純度のアウトプットを提供するために、発現プラットフォーム（CHO細胞、大腸菌、HEK293など）を改良しています。このようなサービスの多様化により、トップクラスのCMOは単なる受託サービスプロバイダーではなく、戦略的イノベーションパートナーとなりつつあります。

どのような規制的・技術的変化が市場の勢いを駆り立てているのか？

世界のGMPタンパク質受託製造市場は、規制の調和と生産技術の絶え間ない革新の両方から恩恵を受けています。FDA、EMA、PMDAなどの規制機関は、生物製剤の製造、バイオシミラー、リスクベースの品質管理に関するガイドラインを強化しており、医薬品開発企業は、実績のあるGMPと国際的な検査態勢を持つCMOと提携するよう求められています。バイオシミラーやバイオベッターが世界的に普及するにつれて、CMOはタンパク質の発現や精製プロセスにおける同等性や一貫性を実証する任務も担っており、高度な分析手法や検証済みのバイオアッセイが必要とされています。

タンパク質工学とバイオプロセスにおける技術の進歩は、CMOの運営方法を変えつつあります。高分解能質量分析、QbD（Quality by Design）、PAT（Process Analytical Technology）、AI主導のプロセス・モデリングなどの技術は、バッチの一貫性を高め、不良率を低減しています。自動クロマトグラフィー、プレフィルドシリンジ、凍結乾燥、コールドチェーンロジスティクスの革新は、高度なタンパク質療法の進化するニーズに対応するため、CMOの製品に統合されつつあります。一方、デジタル製造ツールやクラウドベースの品質管理システムは、リアルタイムのバッチ追跡、監査対応、規制の透明性を確保するために導入されています。このようなシフトは、生物製剤エコシステムにおける受託製造業者の信頼性と戦略的価値を高めています。

世界のGMPタンパク質受託製造市場の成長を牽引しているものは何か？

GMPタンパク質受託製造市場の成長は、生物製剤産業の拡大、アウトソーシング動向の増加、規制要件の進化に直結するいくつかの要因によってもたらされています。第一に、がん、自己免疫疾患、希少疾患、ワクチンプラットフォームにわたる生物製剤およびバイオシミラー開発パイプラインの急増が、GMPに準拠した特殊なタンパク質製造能力に対するかつてない需要を生み出しています。特に中小のバイオテクノロジー企業は、社内の能力ギャップを埋めるためにCMOにアウトソーシングし、多額のインフラ投資をせずに臨床の進捗を加速させています。

第二に、臨床試験と医薬品開発の世界化により、企業は、多国籍のコンプライアンス専門知識と地域横断的なスケーラブルなオペレーションを提供するCMOとの提携を進めています。第三に、シングルユースシステムやモジュラークリーンルームなどの柔軟な製造技術の採用により、CMOはプロジェクトの迅速なターンアラウンドとコスト効率に優れた生産を可能にしています。これと並行して、mRNAワクチン、CRISPRに基づく治療、細胞治療などの新興分野でGMPグレードのタンパク質の使用が増加しており、製造受託パートナーシップに新たな道が開かれつつあります。最後に、規制当局の期待が厳しくなり、技術革新のサイクルが短くなるにつれ、製薬会社は、コンプライアンスを確保し、複雑性を管理し、高度な生物製剤の市場投入スピードを実現するために、経験豊富なCMOをこれまで以上に頼りにしています。

セグメント

製品タイプ（サイトカイン、成長因子、酵素、ホルモン、抗原、その他の製品タイプ）、方法（生体内、生体外）、用途（遺伝子治療、細胞治療）、最終用途（バイオテクノロジー・製薬企業、学術・研究機関、受託研究機関、その他の最終用途）

調査対象企業の例（合計 47注目の企業）

• 53Biologics
• Abgenex
• ACROBiosystems
• AGC Biologics
• Aldevron
• Avioq, Inc.
• Bio-Techne Corporation
• Biovian Oy
• Boehringer Ingelheim BioXcellence
• Eurogentec
• FUJIFILM Diosynth Biotechnologies
• GenScript
• Icosagen
• KBI Biopharma
• Northway Biotech
• Polyplus
• ProBioGen AG
• Rentschler Biopharma SE
• Therapure Biopharma Inc.
• WuXi Biologics

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global GMP Protein Contract Manufacturing Market to Reach US$1.3 Billion by 2030

The global market for GMP Protein Contract Manufacturing estimated at US$800.7 Million in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 8.0% over the analysis period 2024-2030. Cytokines, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$313.1 Million by the end of the analysis period. Growth in the Growth Factors segment is estimated at 9.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$218.1 Million While China is Forecast to Grow at 12.2% CAGR

The GMP Protein Contract Manufacturing market in the U.S. is estimated at US$218.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$267.9 Million by the year 2030 trailing a CAGR of 12.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Global GMP Protein Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is GMP-Grade Protein Manufacturing Critical in Today’s Biopharmaceutical Landscape?

GMP (Good Manufacturing Practice) protein contract manufacturing plays a foundational role in the production of therapeutic proteins, enzymes, and biologics that meet stringent regulatory standards. These proteins, often used in clinical trials or marketed therapies, must be produced under tightly controlled conditions to ensure safety, consistency, and efficacy. Given the complexity and cost of establishing in-house GMP-compliant facilities, many pharmaceutical and biotech firms outsource their protein production needs to specialized contract manufacturing organizations (CMOs) with validated GMP infrastructure and regulatory experience. This model not only reduces capital expenditure but also accelerates time-to-market in a highly competitive and innovation-driven industry.

As biologics dominate new drug pipelines-especially monoclonal antibodies, cytokines, fusion proteins, and therapeutic enzymes-the demand for high-quality, GMP-compliant protein manufacturing continues to surge. These proteins are often highly sensitive to process conditions, requiring advanced expression systems (bacterial, yeast, mammalian, or insect cells), precise purification protocols, and robust quality assurance frameworks. GMP protein manufacturing services encompass upstream cell line development, scale-up, purification, formulation, fill-finish, and release testing, all under strict regulatory oversight. The growing reliance on CMOs for these specialized processes is driven by their proven track record in navigating regulatory submissions and delivering production-ready materials at various clinical and commercial scales.

How Are Biotech Trends and Drug Development Needs Reshaping CMO Service Offerings?

The evolution of biotech pipelines is forcing contract manufacturers to expand their service capabilities to accommodate diverse protein types, complex molecular structures, and accelerated development timelines. With the rising number of orphan drugs, biologics for rare diseases, and personalized therapies entering the pipeline, CMOs are investing in flexible, modular GMP facilities that can handle both small-batch clinical material and large-scale commercial runs. Single-use bioreactors, high-throughput purification systems, and continuous processing methods are being adopted to enhance scalability, reduce cross-contamination risks, and lower operational costs.

Another transformative trend is the shift toward integrated development and manufacturing platforms, where CMOs offer end-to-end services-from gene synthesis and plasmid design to GMP-grade protein expression and final formulation. This one-stop-shop model enables faster transitions from discovery to clinical development, especially valuable for startups and virtual biotechs with limited internal capabilities. Additionally, increasing demand for recombinant proteins used in cell therapy, gene therapy, and vaccine production is prompting CMOs to refine their expression platforms (e.g., CHO cells, E. coli, HEK293) to deliver high-yield, high-purity outputs. This service diversification is turning top-tier CMOs into strategic innovation partners rather than just contract service providers.

What Regulatory and Technological Shifts Are Driving Market Momentum?

The global GMP protein contract manufacturing market is benefiting from both regulatory harmonization and continuous innovation in production technologies. Regulatory bodies such as the FDA, EMA, and PMDA have strengthened guidelines around biologics manufacturing, biosimilarity, and risk-based quality control, prompting drug developers to partner with CMOs that have proven GMP track records and international inspection readiness. As biosimilars and biobetters gain traction worldwide, CMOs are also tasked with demonstrating equivalency and consistency in protein expression and purification processes, necessitating advanced analytical methods and validated bioassays.

Technological progress in protein engineering and bioprocessing is reshaping how CMOs operate. Techniques such as high-resolution mass spectrometry, QbD (Quality by Design), PAT (Process Analytical Technology), and AI-driven process modeling are enhancing batch consistency and reducing failure rates. Innovations in automated chromatography, prefilled syringes, lyophilization, and cold chain logistics are being integrated into CMO offerings to meet the evolving needs of advanced protein therapies. Meanwhile, digital manufacturing tools and cloud-based quality management systems are being deployed to ensure real-time batch tracking, audit readiness, and regulatory transparency. These shifts are increasing both the reliability and strategic value of contract manufacturers in the biologics ecosystem.

What Is Driving Growth Across the Global GMP Protein Contract Manufacturing Market?

The growth in the GMP protein contract manufacturing market is driven by several factors directly linked to the expansion of the biologics industry, increased outsourcing trends, and evolving regulatory requirements. First, the surge in biologics and biosimilar development pipelines-spanning oncology, autoimmune disorders, rare diseases, and vaccine platforms-is generating unprecedented demand for specialized, GMP-compliant protein manufacturing capacity. Small and mid-sized biotech firms, in particular, are outsourcing to CMOs to bridge internal capability gaps and accelerate clinical progress without heavy infrastructure investments.

Second, the globalization of clinical trials and drug development is pushing companies to work with CMOs that offer multinational compliance expertise and scalable operations across regions. Third, the adoption of flexible manufacturing technologies, such as single-use systems and modular cleanrooms, is enabling CMOs to offer faster project turnaround and more cost-efficient production. In parallel, the increasing use of GMP-grade proteins in emerging fields-such as mRNA vaccines, CRISPR-based therapies, and cell therapies-is opening new avenues for contract manufacturing partnerships. Finally, as regulatory expectations tighten and innovation cycles shorten, pharmaceutical firms are relying more than ever on experienced CMOs to ensure compliance, manage complexity, and deliver speed-to-market for advanced biologics.

SCOPE OF STUDY:

The report analyzes the GMP Protein Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Cytokines, Growth Factors, Enzymes, Hormones, Antigens, Other Product Types); Method (In-Vivo, Ex-Vivo); Application (Gene Therapy, Cell Therapy); End-Use (Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• 53Biologics
• Abgenex
• ACROBiosystems
• AGC Biologics
• Aldevron
• Avioq, Inc.
• Bio-Techne Corporation
• Biovian Oy
• Boehringer Ingelheim BioXcellence
• Eurogentec
• FUJIFILM Diosynth Biotechnologies
• GenScript
• Icosagen
• KBI Biopharma
• Northway Biotech
• Polyplus
• ProBioGen AG
• Rentschler Biopharma SE
• Therapure Biopharma Inc.
• WuXi Biologics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • GMP Protein Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Biologics and Biosimilars Drives Growth of GMP-Compliant Protein Manufacturing Services
  • Expansion of Cell and Gene Therapy Pipelines Strengthens the Business Case for Specialized Protein Production Outsourcing
  • Increased Focus on Speed-to-Market in Biopharma Accelerates Adoption of GMP-Qualified CDMOs for Protein Supply
  • Growing Complexity of Biologic Drug Development Spurs Demand for High-Purity, GMP-Grade Protein Reagents
  • Outsourcing Trends Among Emerging Biotech Firms Propel Contract Manufacturing Partnerships for GMP Proteins
  • Regulatory Emphasis on Quality and Batch Consistency Fuels Investment in GMP-Compliant Production Facilities
  • Use of Recombinant Proteins in Vaccine Development Expands Addressable Market for GMP Contract Manufacturers
  • Advancements in Single-Use Bioprocessing Technologies Enhance Flexibility and Scalability of GMP Protein Production
  • Surge in Demand for GMP Proteins in Cell Therapy and Immunotherapy Applications Drives Market Growth
  • Growth in Companion Diagnostics and Personalized Medicine Accelerates Use of GMP Proteins in Assay Development
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World GMP Protein Contract Manufacturing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for GMP Protein Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for GMP Protein Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Cytokines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Cytokines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Cytokines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Hormones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Antigens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Antigens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Antigens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Biotech & Pharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for In-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for In-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for In-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Ex-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Ex-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Ex-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• JAPAN
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 71: Japan Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• CHINA
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 83: China Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• EUROPE
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 95: Europe Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for GMP Protein Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for GMP Protein Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• FRANCE
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 110: France Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• GERMANY
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 122: Germany Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 134: Italy Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 146: UK Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 158: Spain Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 170: Russia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for GMP Protein Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for GMP Protein Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• AUSTRALIA
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 209: Australia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• INDIA
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 221: India Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for GMP Protein Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for GMP Protein Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for GMP Protein Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for GMP Protein Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 335: Iran Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 347: Israel Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 371: UAE Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030
• AFRICA
  • GMP Protein Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 395: Africa Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for GMP Protein Contract Manufacturing by Product Type - Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for GMP Protein Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Cytokines, Growth Factors, Enzymes, Hormones, Antigens and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for GMP Protein Contract Manufacturing by Application - Cell Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for GMP Protein Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy and Gene Therapy for the Years 2015, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for GMP Protein Contract Manufacturing by End-Use - Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for GMP Protein Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies, Academic & Research Institutes, Contract Research Organizations and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for GMP Protein Contract Manufacturing by Method - In-Vivo and Ex-Vivo Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for GMP Protein Contract Manufacturing by Method - Percentage Breakdown of Value Sales for In-Vivo and Ex-Vivo for the Years 2015, 2025 & 2030

IV. COMPETITION